The Shrimp's Secret
In the perpetual twilight of the mesopelagic zone, the cypridinid ostracod, or 'sea firefly,' releases brilliant puffs of blue light to deter predators. The chemistry behind this light is unique, relying on a small molecule, vargulin, and its corresponding luciferase, which we have named 'cypridina luciferase 2' (CLase2). Unlike the firefly luciferase commonly used in laboratories, the CLase2 reaction is faster, brighter, and operates independently of ATP (adenosine triphosphate), making its light output less dependent on the metabolic state of the cell it's in. Our biomedical division recognized this as a potential game-changer for in vivo imaging. The challenge was twofold: modify the reaction to emit in the near-infrared (NIR) window where light penetrates tissue best, and target it specifically to cancer cells. After five years of protein engineering and synthetic chemistry, we have succeeded in creating 'LumiTarget-1,' the first CLase2-based activatable probe for cancer imaging.
Engineering LumiTarget-1
The development process was a masterclass in interdisciplinary science. Our protein engineers used directed evolution to create a mutant form of CLase2, dubbed CLase2-NIR, with a shifted emission peak to 680 nm, a sweet spot for tissue penetration. They then fused this enzyme to a single-chain variable fragment (scFv) antibody designed to bind to HER2, a receptor overexpressed in many breast and gastric cancers. Meanwhile, our chemists synthesized a prodrug version of the vargulin substrate, 'Varg-Pro.' In its inert form, Varg-Pro is non-luminescent and circulates harmlessly in the bloodstream. The magic is in the targeting and activation. When the CLase2-NIR-scFv construct binds to a HER2-positive cancer cell, it is internalized. Inside the cell's acidic environment, a specific linker on the Varg-Pro molecule is cleaved by the protease cathepsin B—an enzyme also upregulated in cancer cells. This releases active vargulin, which immediately reacts with the waiting CLase2-NIR enzyme, generating a burst of NIR light right inside the tumor cell.
Unprecedented Sensitivity in Pre-Clinical Models
In mouse models of HER2-positive breast cancer, the results have been astounding. Intravenous injection of the two components (the targeting enzyme and the prodrug substrate) leads to a specific, strong luminescent signal at the tumor site within 90 minutes. The signal-to-noise ratio is over 100-fold better than with existing firefly luciferase-based systems. Crucially, we have detected micrometastases in lymph nodes and lungs that were invisible to conventional MRI and PET scans. Because the light is only produced where both the enzyme and the activated substrate co-localize inside a target cell, there is virtually no background signal from healthy tissue or from the probe circulating in the blood. This allows for real-time, high-contrast imaging of tumor burden, response to therapy, and early recurrence. Furthermore, the system is safe; all components are biodegradable and non-radioactive.
The Road to Clinical Translation
The potential applications are transformative. LumiTarget-1 could enable surgeons to see the exact margins of a tumor in real time during an operation, ensuring complete removal. It could allow oncologists to monitor the effectiveness of a chemotherapy regimen within days, not months, by tracking the dimming of the luminescent signal as cancer cells die. We are already developing a suite of probes targeting different cancer markers (PSMA for prostate cancer, EGFR for lung cancer, etc.). The first Phase I clinical trials for intraoperative imaging in breast cancer are scheduled to begin in 18 months, pending regulatory approval. This research exemplifies a powerful convergence: the defensive chemistry of a tiny, deep-sea crustacean, honed by evolution, is being repurposed into one of the most sensitive diagnostic tools ever conceived in the fight against one of humanity's greatest scourges. The light from the ocean's depths is guiding us toward a future of more precise, personalized, and effective medicine.